Inclusion Criteria:

- Women with endometrial cancer with high risk histologic subtypes including
carcinosarcoma, grade 3 endometrioid, serous, clear cell, undifferentiated
adenocarcinoma

- Clinical stage 1 disease- no evidence of metastatic disease beyond the uterus by
physical exam or preoperative imaging if performed.

- Patients who have signed an approved informed consent.

- Patients who will undergo surgery that includes a abdominal hysterectomy and
bilateral pelvic and inframesenteric para-aortic lymphadenectomy via laparotomy,
laparoscopy or robotic-assisted.

Exclusion Criteria:

- Patients with evidence of metastatic disease on preoperative imaging.

- Patients with evidence of intraperitoneal metastatic disease intraoperatively
(patients with suspicious retroperitoneal lymph nodes intraoperatively will still be
included).

- Patients with known allergy to triphenylmethane compounds.

- Contraindications for MRI: The contraindications for MR are as per departmental
safety guidelines. Specifically patients with cardiac pacemaker, cochlear implants,
insulin pumps, nerve stimulators, lead wires, prosthetic heart valves or haemostatic
clips will be excluded.

- Contraindications for contrast (Gadovosfeset trisodium):

1. History of a prior allergic reaction to a gadolinium-based contrast agent.

2. High risk for nephrogenic systemic fibrosis. The precautions as per routine
departmental protocol for use of Gadolinium-based contrast agent will be
applied (For the purpose of this study, patients with eGFR less than 30 will be
excluded from the study).

3. Patients with documented prolonged QTc.

- Pregnant patient.

- Patients with previous retroperitoneal surgery.

- Patients with previous history of pelvic/abdominal radiation.

- Patients with recurrent endometrial cancer.

- Any patient treated with neoadjuvant chemotherapy and/or radiation.